Why is ADMA Biologics facing a securities class action lawsuit?

Investors allege ADMA Biologics made misleading statements about revenue practices, internal controls, and related-party transactions.

What are investors claiming about ADMA Biologics’ revenue reporting?

The complaint alleges the company used channel stuffing to create the appearance of stronger revenue growth.

What is channel stuffing in the ADMA Biologics lawsuit?

Channel stuffing refers to shipping more products to customers than needed to boost reported sales figures temporarily.

Why is channel stuffing a concern for investors?

It can make revenue appear stronger than actual demand, potentially misleading investors about business performance.

What are related-party transactions in the ADMA Biologics allegations?

The lawsuit claims the company engaged in an undisclosed transaction involving a related party.

Why are related-party transactions important to shareholders?

Such transactions may create conflicts of interest and are typically expected to be disclosed to investors.

What are investors alleging about ADMA Biologics’ internal controls?

Plaintiffs claim the company lacked adequate controls to ensure accurate financial reporting and oversight.

How could weak internal controls affect ADMA Biologics?

Control deficiencies may increase the risk of accounting errors, compliance issues, and inaccurate disclosures.

What are investors alleging ADMA Biologics failed to disclose?

The complaint claims the company did not fully reveal revenue practices, related-party dealings, and control weaknesses.

Who may qualify to participate in the ADMA Biologics class action?

Investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 may be eligible if they suffered losses.

What is the deadline to seek lead plaintiff status in the ADMA Biologics lawsuit?

Investors seeking appointment as lead plaintiff must file a motion by August 10, 2026.

What is a securities class action lawsuit?

A securities class action allows investors to collectively pursue claims against a company for misleading statements or omissions.

What does the term “class period” mean in a securities lawsuit?

The class period is the timeframe during which alleged misleading statements occurred and investors may have purchased securities.

What is a lead plaintiff in a securities class action?

The lead plaintiff is the investor selected by the court to represent the interests of all shareholders and help oversee the litigation.

How do investors receive compensation from a securities class action settlement?

If a settlement is reached, investors submit claim forms documenting eligible purchases and losses to receive a share of the settlement fund.

ADMA Biologics, Inc - Faruqi & Faruqi LLP

ADMA Biologics, Inc

Join Action

Case Details

Ticker ADMA

Class Period 08/09/2024 - 03/25/2026

Lead Plaintiff Deadline 08/10/2026

Days Left to Seek Plaintiff

If you are an ADMA Biologics investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. (“ADMA Biologics” or the “Company”) (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ADMA Biologics engaged in an undisclosed related party transaction; (2) ADMA Biologics used channel stuffing to create an appearance of revenue; (3) ADMA Biologics lacked adequate internal controls; and (4) as a result, defendants’ statements about ADMA Biologics’ business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Lead Plaintiff Deadline: August 10, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

ADMA Biologics, Inc

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify